<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="178173">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00775658</url>
  </required_header>
  <id_info>
    <org_study_id>071260</org_study_id>
    <nct_id>NCT00775658</nct_id>
  </id_info>
  <brief_title>Olopatadine Eye Drops and Allergy Skin Testing</brief_title>
  <official_title>Effect of Olopatadine Hydrochloride 0.2% Ophthalmic Solution on Epicutaneous Skin Prick Testing With Histamine and Saline</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Use of olopatadine ophthalmic solution (eye drops) will decrease allergy skin test
      reactivity.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The difference in area (mm2) of the wheal and flare histamine skin test response during treatment with olopatadine compared to placebo.</measure>
    <time_frame>primary outcome measure assessed at baseline, study visit day &gt;5 and study visit day &gt;17.</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Allergic Rhinitis</condition>
  <condition>Allergic Conjunctivitis</condition>
  <arm_group>
    <arm_group_label>olopatadine 0.2% opthalmic solution</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo, normal saline opthalmic solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>olopatadine 0.2% opthalmic solution</intervention_name>
    <arm_group_label>olopatadine 0.2% opthalmic solution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo, normal saline opthalmic solution</intervention_name>
    <arm_group_label>placebo, normal saline opthalmic solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults aged 18 to 75 years

          -  Healthy volunteers (no major illnesses or active symptoms)

        Exclusion Criteria:

          -  Known allergy or hypersensitivity to the drugs or components

          -  Pregnant or nursing women

          -  Women wishing to become pregnant during the study's duration

          -  Use of topical or oral medications with antihistaminic activity for 14 days
             proceeding randomization

          -  Dermatographism as evidenced on skin testing on visit 1

          -  Chronic urticaria active within the past 6 months

          -  Severe hypertension

          -  Psychiatric diagnoses which could potentially affect medication compliance, such as
             schizophrenia or delusional disorders, as determined by the investigator obtaining
             informed consent and based on the subject's past medical history

          -  Inability to provide informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Vanderbilt Asthma, Sinus and Allergy Program Research</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2008</verification_date>
  <lastchanged_date>October 17, 2008</lastchanged_date>
  <firstreceived_date>October 17, 2008</firstreceived_date>
  <responsible_party>
    <name_title>John Fahrenholz, MD</name_title>
    <organization>Vanderbilt University Medical Center</organization>
  </responsible_party>
  <keyword>allergy</keyword>
  <keyword>skin testing</keyword>
  <keyword>eye drops</keyword>
  <keyword>antihistamines</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Conjunctivitis</mesh_term>
    <mesh_term>Conjunctivitis, Allergic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Olopatadine Hydrochloride</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
